Trial 1B-15-2


A Phase II Randomized, Double-Blind, Placebo-Controlled Trial of Radium-223 Dichloride in Combination with Exemestane and Everolimus versus Placebo in Combination with Exemestane and Everolimus when Administered to Metastatic HER2 Negative Hormone Receptor Positive Breast Cancer Subjects with Bone Metastases

Type: Treatment
Phase: Phase II
Status: Not Open (Closed)
Treatments: Biological Response Modifier, Radiation: Other
Randomized: Yes
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Janice Lu, M.D.
Other Trial Staff:  Richa Aggarwal, D.M., Monica Flores, D.M., Victoria Banerjee, R.N., Victoria Banerjee, Coordinator, Grace Facio, Coordinator, Margarita Carranza, D.M., America Casillas-Lopez, Coordinator, Kristy Watkins, R.N.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.